1
66
inflammation of the joints and eliminate any streptococ-
cal organism remaining in her system. The patient’s
condition improved within 48 hours. By the second
week, the involuntary movements had disappeared. The
patient has resumed normal activities and has been fol-
lowed up in our clinics for about 8 months. No recur-
rence was reported.
disease of adult onset with an unremitting autosomal
dominant movement disorder and dementia; unlike in
Huntington disease, neuroimaging in Sydenham's chorea
is normal and other family members are usually unaf-
fected. Our patient manifested the main features of SC
2
as listed by WHO viz: involuntary movements, hypoto-
nia, and muscular weakness. Chorea can be generalized
2
or unilateral . Patients with SC may also have psychiat-
ric symptoms such as depression, anxiety, personality
7
Discussion
changes, etc Whether the psychological manifestations
are secondary to the movement disorder or an integral
part of the disease is not clear. It is also common for
some patients with SC to present with other manifesta-
Reliable data on the incidence of SC and RF are scarce.
The incidence of SC in Africa is not known but one
4
2
pooled study has put it at 8.8% . No known data exists
tions of RF . Our patient had chronic arthralgia but had
5
for SC in Nigeria but Okoroma et al in Enugu reported
no clinical evidence of carditis. This may not be unusual
as carditis has been documented to occur in only about
it as being rare in their study. The diagnosis of SC de-
pends on a high index of suspicion. Depending on the
experience of the health provider the diagnosis may be
entirely missed due to lack of awareness of the clinical
entity. Our patient presented early to a peripheral hospi-
tal where the diagnosis was missed delaying manage-
ment of her rheumatic chorea.
9
40-50% of patients with ARF at the time of diagnosis .
Averagely, rheumatic chorea resolves spontaneously
within 3-6 months but may last longer if untreated. With
treatment our patient’s symptoms resolved within two
weeks. Fast resolution with t,6r,e7atment has also been re-
4
ported by other researchers . About 20% of patients
Considering the high contribution of RHD to acquired
may experience recurrences and relapses, usually within
2 years after the initial attack and this underscores the
need for adequate follow up.
Treatment of SC is typically limited to supportive care,
palliative medications, to eliminate streptococci and
treat movement disorders, and long-term follow up.
6
,7
7
heart disease in Sub-Saharan Africa , the low incidence
of SC appears paradoxical and the explanation is not
clear. Studies of ARF outbreak in the USA during the
1
990’s attributed SC to highly virulent mucoid strains of
8
group A Streptococci . Though, it may be attractive to
speculate that the strains of group A Streptoccoci in our
environment are less virulent and therefore have lower
propensity for causing SC, further studies need to be
done on the virulence and immunogenicity of the strains
of group A Streptoccoci in our environment that cause
ARF to establish that.
Conclusion
Sydenham’s chorea is a disabling manifestation of rheu-
matic fever, and its rarity in sub-Saharan Africa may
have contributed to cases being misdiagnosed or even
missed. It requires proper diagnosis as prompt and ap-
propriate medications can bring quick resolution to
symptoms. There is need for continual awareness crea-
tion on manifestations of ARF and its proper manage-
ments.
4
According to Jones criteria chorea alone is sufficient
4
for diagnosis of RF provided other causes of chorea had
been excluded. Other possible causes of childhood cho-
rea include cerebrovascular accidents, collagen vascular
diseases, drug intoxication, hyperthyroidism, Wilson's
disease, Huntington's disease, abetalipoproteinemia,
2
Lesch-Nyhan syndrome and hormonal imbalances .
Conflict of interest: None
Funding: None
Unlike SC, Huntington chorea is generally a
References
1
2
.
.
Barbeau A, Duvoisin RC, Gersten-
brand F, Lakke JP, Marsden CD,
Stern G. Classification of ex-
trapyramidal disorders. Proposal
for an international classification
and glossary of terms. J Neurol
Sci. 1981;51(2):311-27.
WHO Expert Consultation on
Rheumatic Fever and Rheumatic
Hear Disease. Rheumatic fever
and rheumatic heart disease: report
of a WHO Expert Consultation,
Geneva, 29 Oct – 1 Nov 2001.
Geneva: WHO, 2004 (WHO Tech-
nical Report Series No.923).
3. Bisno A. Non-cardiac manifesta-
7. Walker KG, Wilmshurst JM. An
update on the treatment of Syden-
ham’s chorea: the evidence for
established and evolving interven-
tions. Ther Adv Neurol Disord
2010; 3(5):301-309.
8. Woo CLF, Liu KT,Young BWY.
Acute Rheumatic Fever Presenting
with Sydenham's chorea. HK J
Paediatr (new series) 2003;8:198-
202.
9. Busari O; Opadijo G; Fasae
A.Acute Rheumatic Fever: A Pub-
lic Health Concern in Resource-
Poor Settings Archives Medical
Review Journal 2013; 22(2):153-
169
tions of rheumatic fever. In: Narula
et al., editors. Rheumatic fever.
Washington, DC, American Regis-
try of Pathology, 1994:245–256.
4. Michael DS, Tracey RH. The
worldwide epidemiology of acute
rheumatic fever and rheumatic
heart disease. Clinical Epidemiol-
ogy 2011;3:67–84.
5. Okoroma EO, Ihenacho IN, An-
yanwu CH. Rheumatic fever in
Nigerian children. A prospective
study of 66 patients. Am J Dis
Child. 1981; 135: 236–238.
6
.
Carapetis JR, Currie BJ. Rheu-
matic chorea in northern Australia:
a clinical and epidemiological study.
Arch Dis Child 1999; 80:353-8.